Is Vernalis plc The Perfect Partner For BTG plc In Your Portfolio?

Should you buy Vernalis plc (LON: VER) alongside BTG plc (LON: BTG)?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in pharmaceutical company Vernalis (LSE: VER) have surged by over 15% today as the company received very positive news flow regarding a drug approval. In fact, the company has received approval from the US Food and Drug Administration (FDA) for a New Drug Application (NDA) for Tuzistra XR, which is an extended release oral suspension combination of codeine and chlorpheniramine used to treat the symptoms of the common cold.

Commenting on the approval, Vernalis’ CEO, Ian Garland, said it is a ‘very significant moment in the evolution of Vernalis to a commercial stage speciality pharmaceutical company’. Investors in the company certainly agree, as evidenced by today’s share price rise. And, with Vernalis having delivered capital gains of 80% in the last year, is it the perfect partner for larger sector peer, BTG (LSE: BTG), in your portfolio?

Track Record

Looking back at the two companies’ track records of profitability, BTG offers much more stability than its smaller peer. That is, of course, to be expected, since BTG is a more mature company, while Vernalis is still transitioning towards being a commercial stage pharmaceutical company. As such, for investors looking for greater stability, BTG appears to be a sound play, since it has delivered growing profitability over the last two years, while Vernalis remains a loss-making company.

Looking Ahead

For investors in BTG, the future appears to be very bright. That’s because it is forecast to deliver a rapid growth in its bottom line, with an increase of 22% pencilled in for next year, followed by growth of 48% in the year after. And, despite this, investor sentiment in BTG has remained relatively weak, with shares in the company being down 9% since the turn of the year. This has helped to push them, however, to a valuation that indicates the company’s share price could be set to move considerably higher. For example, BTG has a price to earnings growth (PEG) ratio of just 0.5, which equates to growth at a very reasonable price.

Meanwhile, Vernalis is set to see its losses widen over the next two years as it continues to seek approval for its appealing pipeline. However, the company has a relatively strong cash position and so is likely to be able to cope with anticipated pretax losses of around £36m over the next two years. Furthermore, with investor sentiment in the company being so strong, further rounds of financing are likely to be well-supported and mean that Vernalis can continue to progress with new drugs and additional approvals moving forward.

Risk

Clearly, all pharmaceutical companies carry a degree of risk, since the outcome of regulatory approvals is a known unknown. However, larger firms such as BTG offer more stability than smaller peers such as Vernalis, since (as mentioned) it is a highly profitable company with strong growth potential. And, looking ahead, this could prove to be a catalyst that pushes its share price higher.

Meanwhile, Vernalis remains a company with considerable future potential in the form of an improving pipeline and adequate financing. So, while it is a relatively risky stock, it could be worth buying alongside BTG – especially if you have a long term timeframe.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens has no position in any shares mentioned. The Motley Fool UK has recommended BTG. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »